vs
Amphastar Pharmaceuticals, Inc.(AMPH)とプラグパワー(PLUG)の財務データ比較。上の社名をクリックして会社を切り替えられます
プラグパワーの直近四半期売上が大きい($225.2M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.2倍)。Amphastar Pharmaceuticals, Inc.の純利益率が高く(13.3% vs -375.6%、差は389.0%)。プラグパワーの前年同期比売上増加率が高い(17.6% vs -1.8%)。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い($24.6M vs $-153.0M)。過去8四半期でプラグパワーの売上複合成長率が高い(36.8% vs 3.2%)
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
プラグパワー社は米国企業で、水素燃料電池と電解槽システムの開発を事業とし、電動設備や電気自動車に使用される従来のバッテリーを代替する製品を提供している。本社はニューヨーク州スリンガーランズにあり、ワシントン州スポケーンとニューヨーク州ロチェスターにも事業拠点を構えている。
AMPH vs PLUG — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $183.1M | $225.2M |
| 純利益 | $24.4M | $-846.0M |
| 粗利率 | 46.8% | 2.4% |
| 営業利益率 | 19.4% | -338.9% |
| 純利益率 | 13.3% | -375.6% |
| 売上前年比 | -1.8% | 17.6% |
| 純利益前年比 | -35.7% | 36.7% |
| EPS(希薄化後) | $0.51 | $-0.70 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $225.2M | ||
| Q3 25 | $191.8M | $177.1M | ||
| Q2 25 | $174.4M | $174.0M | ||
| Q1 25 | $170.5M | $133.7M | ||
| Q4 24 | $186.5M | $191.5M | ||
| Q3 24 | $191.2M | $173.7M | ||
| Q2 24 | $182.4M | $143.3M | ||
| Q1 24 | $171.8M | $120.3M |
| Q4 25 | $24.4M | $-846.0M | ||
| Q3 25 | $17.4M | $-361.9M | ||
| Q2 25 | $31.0M | $-227.1M | ||
| Q1 25 | $25.3M | $-196.7M | ||
| Q4 24 | $38.0M | $-1.3B | ||
| Q3 24 | $40.4M | $-211.2M | ||
| Q2 24 | $37.9M | $-262.3M | ||
| Q1 24 | $43.2M | $-295.8M |
| Q4 25 | 46.8% | 2.4% | ||
| Q3 25 | 51.4% | -67.9% | ||
| Q2 25 | 49.6% | -30.7% | ||
| Q1 25 | 50.0% | -55.3% | ||
| Q4 24 | 46.5% | -122.5% | ||
| Q3 24 | 53.3% | -57.6% | ||
| Q2 24 | 52.2% | -91.6% | ||
| Q1 24 | 52.4% | -132.3% |
| Q4 25 | 19.4% | -338.9% | ||
| Q3 25 | 13.2% | -197.0% | ||
| Q2 25 | 24.2% | -101.7% | ||
| Q1 25 | 21.9% | -133.5% | ||
| Q4 24 | 24.2% | -678.7% | ||
| Q3 24 | 29.8% | -124.4% | ||
| Q2 24 | 30.3% | -170.7% | ||
| Q1 24 | 27.9% | -215.7% |
| Q4 25 | 13.3% | -375.6% | ||
| Q3 25 | 9.0% | -204.4% | ||
| Q2 25 | 17.8% | -130.5% | ||
| Q1 25 | 14.8% | -147.1% | ||
| Q4 24 | 20.4% | -697.5% | ||
| Q3 24 | 21.1% | -121.5% | ||
| Q2 24 | 20.8% | -183.0% | ||
| Q1 24 | 25.1% | -245.9% |
| Q4 25 | $0.51 | $-0.70 | ||
| Q3 25 | $0.37 | $-0.31 | ||
| Q2 25 | $0.64 | $-0.20 | ||
| Q1 25 | $0.51 | $-0.21 | ||
| Q4 24 | $0.74 | $-1.61 | ||
| Q3 24 | $0.78 | $-0.25 | ||
| Q2 24 | $0.73 | $-0.36 | ||
| Q1 24 | $0.81 | $-0.46 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $368.5M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $978.1M |
| 総資産 | $1.6B | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $368.5M | ||
| Q3 25 | $276.2M | $165.9M | ||
| Q2 25 | $231.8M | $140.7M | ||
| Q1 25 | $236.9M | $295.8M | ||
| Q4 24 | $221.6M | $205.7M | ||
| Q3 24 | $250.5M | $93.9M | ||
| Q2 24 | $217.8M | $62.4M | ||
| Q1 24 | $289.6M | $172.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | $3.9M | ||
| Q2 24 | $586.9M | $3.7M | ||
| Q1 24 | $594.0M | $3.8M |
| Q4 25 | $788.8M | $978.1M | ||
| Q3 25 | $776.7M | $1.4B | ||
| Q2 25 | $757.5M | $1.7B | ||
| Q1 25 | $751.3M | $1.9B | ||
| Q4 24 | $732.3M | $1.7B | ||
| Q3 24 | $727.7M | $3.0B | ||
| Q2 24 | $713.3M | $3.0B | ||
| Q1 24 | $672.4M | $2.9B |
| Q4 25 | $1.6B | $2.6B | ||
| Q3 25 | $1.7B | $3.1B | ||
| Q2 25 | $1.6B | $3.4B | ||
| Q1 25 | $1.6B | $3.6B | ||
| Q4 24 | $1.6B | $3.6B | ||
| Q3 24 | $1.5B | $4.7B | ||
| Q2 24 | $1.5B | $4.8B | ||
| Q1 24 | $1.6B | $4.8B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-148.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-153.0M |
| FCFマージンFCF / 売上 | 13.4% | -67.9% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-647.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-148.6M | ||
| Q3 25 | $52.6M | $-89.8M | ||
| Q2 25 | $35.6M | $-191.8M | ||
| Q1 25 | $35.1M | $-105.6M | ||
| Q4 24 | $29.0M | $-131.2M | ||
| Q3 24 | $60.0M | $-174.9M | ||
| Q2 24 | $69.1M | $-254.7M | ||
| Q1 24 | $55.3M | $-167.7M |
| Q4 25 | $24.6M | $-153.0M | ||
| Q3 25 | $47.2M | $-117.5M | ||
| Q2 25 | $25.0M | $-230.4M | ||
| Q1 25 | $24.4M | $-146.0M | ||
| Q4 24 | $16.6M | $-165.2M | ||
| Q3 24 | $46.2M | $-234.2M | ||
| Q2 24 | $63.1M | $-356.0M | ||
| Q1 24 | $46.5M | $-260.3M |
| Q4 25 | 13.4% | -67.9% | ||
| Q3 25 | 24.6% | -66.4% | ||
| Q2 25 | 14.3% | -132.5% | ||
| Q1 25 | 14.3% | -109.2% | ||
| Q4 24 | 8.9% | -86.3% | ||
| Q3 24 | 24.1% | -134.8% | ||
| Q2 24 | 34.6% | -248.4% | ||
| Q1 24 | 27.1% | -216.5% |
| Q4 25 | 4.5% | 1.9% | ||
| Q3 25 | 2.8% | 15.6% | ||
| Q2 25 | 6.1% | 22.2% | ||
| Q1 25 | 6.3% | 30.3% | ||
| Q4 24 | 6.7% | 17.7% | ||
| Q3 24 | 7.2% | 34.1% | ||
| Q2 24 | 3.3% | 70.7% | ||
| Q1 24 | 5.1% | 77.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PLUG
| Sales Of Equipment And Related Infrastructure | $111.6M | 50% |
| Services Performed On Fuel Cell Systems And Related Infrastructure | $41.5M | 18% |
| Power Purchase Agreements | $36.1M | 16% |
| Sale Of Cryogenic Equipment | $20.0M | 9% |
| Sales Of Fuel Cell Systems | $11.2M | 5% |
| Other | $4.8M | 2% |